Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC januari 12, 20240OpmerkingenEN NL Read More
Jaarverslag 2023 (officiële ESEF-versie) december 30, 20230OpmerkingenJaarverslag 2023 (officiële ESEF-versie)Read More
Jaarverslag 2023 (officiële ESEF-versie) december 30, 20230OpmerkingenJaarverslag 2023 (officiële ESEF-versie)Read More
Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas december 28, 20230OpmerkingenEN NL Read More
Oxurion Receives Transparency Notification from Negma Group december 6, 20230OpmerkingenEN NL Read More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC december 1, 20230OpmerkingenEN NL Read More
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema november 20, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas november 19, 20230OpmerkingenEN NL Read More
Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year november 16, 20230OpmerkingenEN Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas november 16, 20230OpmerkingenEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC november 15, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas november 6, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas november 3, 20230OpmerkingenEN NL Read More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC oktober 30, 20230OpmerkingenEN NL Read More
Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial oktober 25, 20230OpmerkingenEN Read More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC oktober 20, 20230OpmerkingenEN NL Read More
